Hormone replacement therapy for osteoporosis

References

Citations

1. National Institutes of Health (2003). Women's Health Initiative. Available online: http://www.nhlbi.nih.gov/whi/.

2. Fletcher SW, Colditz GA (2002). Failure of estrogen plus progestin therapy for prevention. JAMA, 288(3): 366–368.

3. Shumaker SA, et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative memory study: A randomized controlled trial. JAMA, 289(20): 2651–2662.

4. Harris ST, et al. (2001). Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 86(5): 1890–1897.

5. Greenspan SL, et al. (2003). Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women. JAMA, 289(19): 2525–2533.

6. Prestwood KM, et al. (2003). Ultralow-dose micronized 17 B-estradiol and bone density and bone metabolism in older women. JAMA, 290(8): 1042–1048.

7. Drugs for prevention and treatment of postmenopausal osteoporosis (2005). Treatment Guidelines From the Medical Letter, 3(38): 69–74.

Author:	Robin Parks, MS	Last Updated: December 1, 2006
Medical Review:	Joy Melnikow, MD, MPH - Family Medicine Carla J. Herman, MD, MPH - Internal Medicine
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.